Sandostatin
Links shared publicly online about this topic
SANDOSTATIN LAR DEPOT (Octreotide) drug information from MPR
empr.com — “SANDOSTATIN LAR DEPOT (Octreotide) drug information for Acromegaly from MPR including side effects, drug interactions, dosing, contraindications and precautions.” View full resource at empr.com
Most Recently Shared on March 8, 2010 at 6:35 am By:
MPR News: SANDOSTATIN LAR DEPOT: Monograph added. http://bit.ly/dsAzuN
New study first to confirm Sandostatin LAR controls tumor growth in patients with rare gastrointestinal tumors
novartis.com — “Basel, January 13, 2009 - Sandostatin LAR (octreotide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuroendocrine tumors (NETs) of the midgut, according to interim data presented today at the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology.” View full resource at novartis.com
Most Recently Shared on January 27, 2009 at 11:40 am By:
New study first to confirm Sandostatin® LAR® controls tumor growth in patients with rare gastrointestinal tumors : http://twurl.nl/6w8wgf
Octreotide LAR in acromegaly Ppt Powerpoint Presentation slides sensible Medical Slideshow About Sandostatin LAR Depot (octreotide acetate)
slideworld.org — “Powerpoint Octreotide LAR in acromegaly Slides by sensible kau About Sandostatin LAR Depot (octreotide acetate) Download Free Medical Powerpoint Presentations” View full resource at slideworld.org
Most Recently Shared on November 29, 2009 at 10:45 pm By:
Medical Templates Health Organization
Octreotide LAR in acromegaly: here in this ppt, i took article and summarized it in slide, of course after understa... http://bit.ly/7qGpRh
Comments of using Sandostatin, Lexapro (study 4193513) - eHealthMe.com
ehealthme.com — “Does Lexapro increase urinary 5-HIAA or blood chromagranin A?” View full resource at ehealthme.com
Most Recently Shared on March 13, 2012 at 8:57 pm By:
Does Lexapro increase urinary 5-HIAA or blood chromagranin A? http://t.co/k1FEjobl
Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors
news-medical.net — “A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.” View full resource at news-medical.net
Most Recently Shared on October 11, 2010 at 12:05 pm By:
Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors: A Novart... http://bit.ly/b0LmUf
Newly Published Phase III Data Show Novartis Drug Sandostatin® LAR Depot Reduced Risk Of Disease Progression By 66% In Advanced NET Patients
medicalnewstoday.com — “Data published in the journal of clinical oncology show that patients with advanced neuroendocrine tumors (net) of the midgut who were treated with sandostatin® lar depot (octreotide acetate f” View full resource at medicalnewstoday.com
Most Recently Shared on October 2, 2009 at 12:33 pm By:
Newly Published Phase III Data Show Novartis Drug Sandostatin® LAR Depot Reduced Risk Of Disease Progression By.. http://bit.ly/ZG354
UPDATE 1-Novartis drug combo cuts pancreatic tumour size | Reuters
reuters.com — “* Afinitor and Sandostatin LAR promising in Phase II trial * Afinitor is one of Novartis's most important new drugs (Adds further details) ZURICH, June 24 (Reuters) - A combination of two drugs” View full resource at reuters.com
Most Recently Shared on June 25, 2009 at 6:04 pm By:
Afinitor and Sandostatin LAR cut pancreatic tumors in half in 80% of patients in a Phase II trial http://tiny.cc/Ufb5j
Medical News: Octreotide Doesn't Prevent Diarrhea in Anorectal CA - in Hematology/Oncology, Other Cancers from MedPage Today
medpagetoday.com — “Octreotide (Sandostatin) appears to hold little benefit for prevention of diarrhea induced by chemotherapy and radiation in rectal and anal cancer patients, researchers discovered, even though there h” View full resource at medpagetoday.com
Most Recently Shared on March 25, 2010 at 2:37 pm By:
Octreotide Doesn't Prevent Diarrhea in Anorectal CA (CME/CE, with audio) Octreotide (Sandostatin) appears to hold lit.. http://bit.ly/dtI2WN
Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer
physorg.com — “In many cancers, octreotide acetate (Sandostatin) has been reported to control the diarrhea that can accompany chemotherapy. However, for patients receiving combined chemotherapy and radiation for anal or rectal cancers, the drug proved no better than a placebo in a randomized trial that was published ...” View full resource at physorg.com
Most Recently Shared on March 24, 2010 at 9:21 pm By:
PhysOrg Health News Health News
Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer http://tw.physorg.com/188668258
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
Novartis
We provide healthcare solutions that address the evolving needs of patients and societies worldwide.
-
Medical Templates
Download medical powerpoint templates on all medical related topics for making fabulous medical powerpoint presentations.
Advertisement
